Literature DB >> 1373283

HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587.

E Tramontano1, Y C Cheng.   

Abstract

The dipyridodiazepinone derivative 6,11-dihydro-11-cyclopropyl-4-methyldipyrido[2,3-b:2',3'-e]-[1,4] diazepin-6-one (BI-RG-587) selectively inhibits human immunodeficiency virus type 1 (HIV-1) replication by suppressing HIV-1 reverse transcriptase activity. Both RNA- and DNA-dependent polymerase associated activities of this enzyme were found to be inhibited by BI-RG-587 in a pattern dependent on the template used. The lowest IC50 values were obtained using poly(rC)-oligo(dG)12-18 and poly(dA)-oligo(dT)12-18 as template-primer. For the RNA-dependent activity poly(rC)-oligo(dG)12-18 and dGTP appeared to enhance the inhibition of the RNA-dependent enzyme activity by BI-RG-587, with the effect of poly(rC)-oligo(dG)12-18 dominating that of dGTP. Poly(rA)-oligo(dT)10 seemed to decrease the inhibition whereas poly(rU)-oligo(dA)12-18 or poly(rG)-oligo-(dC)12-18 had no effect. dATP, dTTP and dCTP, three nucleotide triphosphates, also had no impact on the inhibition. Differences were observed for the template-dependent action of BI-RG-587 against the DNA-dependent enzyme activity. Both substrates were required to allow the inhibition by BI-RG-587 in the poly(dC)-oligo(dG)12-18 and dGTP reaction, whereas only the template and enzyme interaction seemed to be necessary for the poly(dA)-oligo(dT)12-18 and dTTP reaction. The different behaviors of DNA- and RNA-dependent DNA polymerase activities could indicate either the presence of different active sites for distinct activities or the presence of a unique active site with different configurations depending upon the template used. Also, BI-RG-587 showed a mutually exclusive inhibition when combined with two other classes of HIV-1 RT inhibitors represented by phosphonoformic acid and 3'-azido-3'-dideoxythymidine triphosphate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373283     DOI: 10.1016/0006-2952(92)90515-k

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  13 in total

Review 1.  Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.

Authors:  A Bardsley-Elliot; C M Perry
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

2.  Multiple weak intercalation as a strategy for the inhibition of polymerases.

Authors:  Nitin Jain; Simon H Friedman
Journal:  Bioorg Med Chem Lett       Date:  2018-12-13       Impact factor: 2.823

3.  The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1.

Authors:  D W Rodgers; S J Gamblin; B A Harris; S Ray; J S Culp; B Hellmig; D J Woolf; C Debouck; S C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

Review 4.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

5.  Analysis of the combined effect of two linear inhibitors on a single enzyme.

Authors:  J J Martinez-Irujo; M L Villahermosa; J Mercapide; J F Cabodevilla; E Santiago
Journal:  Biochem J       Date:  1998-02-01       Impact factor: 3.857

6.  Structure-activity relationship of pyrrolyl diketo acid derivatives as dual inhibitors of HIV-1 integrase and reverse transcriptase ribonuclease H domain.

Authors:  Giuliana Cuzzucoli Crucitti; Mathieu Métifiot; Luca Pescatori; Antonella Messore; Valentina Noemi Madia; Giovanni Pupo; Francesco Saccoliti; Luigi Scipione; Silvano Tortorella; Francesca Esposito; Angela Corona; Marta Cadeddu; Christophe Marchand; Yves Pommier; Enzo Tramontano; Roberta Costi; Roberto Di Santo
Journal:  J Med Chem       Date:  2015-02-11       Impact factor: 7.446

7.  Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases.

Authors:  Francesca Esposito; Tatyana Kharlamova; Simona Distinto; Luca Zinzula; Yung-Chi Cheng; Ginger Dutschman; Giovanni Floris; Patrick Markt; Angela Corona; Enzo Tramontano
Journal:  FEBS J       Date:  2011-03-16       Impact factor: 5.542

8.  Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs.

Authors:  G Maga; U Hübscher; M Pregnolato; D Ubiali; G Gosselin; S Spadari
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

9.  Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro.

Authors:  M Baba; S Shigeta; S Yuasa; H Takashima; K Sekiya; M Ubasawa; H Tanaka; T Miyasaka; R T Walker; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

10.  The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.

Authors:  Joy Y Feng; John K Ly; Florence Myrick; Derrick Goodman; Kirsten L White; Evguenia S Svarovskaia; Katyna Borroto-Esoda; Michael D Miller
Journal:  Retrovirology       Date:  2009-05-13       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.